FDA Approves Roche’s HER2 Companion Diagnostic for Biliary Tract Cancer Treatment
The PATHWAY HER2 test is a CDx for HER2-positive biliary tract cancer for targeted treatment with Jazz Pharmaceuticals' ZIIHERA.
Tag: CDx
All
Latest
All
Latest
QIAGEN and Myriad Genetics Partner on Companion Diagnostics for Cancer
QIAGEN and Myriad Genetics announced a new master collaboration agreement to develop companion diagnostic tests in the field of cancer.
All
Latest
FDA Approves Guardant Health’s CDx Liquid Biopsy for Breast Cancer Patients
The FDA approved the Guardant360 CDx liquid biopsy test as a companion diagnostic for metastatic breast cancer patients with ESR1 mutations.
FDA Approves First NGS-Based CDx for RET Fusion-Positive NSCLC
Thermo Fisher Scientific’s Oncomine Dx Target Test simultaneously evaluates 23 genes clinically associated with NSCLC.
Read More
Thermo Fisher, Hengrui Therapeutics to Develop CDx for NSCLC
The companion diagnostic will leverage the Oncomine Precision Assay to identify non-small cell lung cancer patients with HER2 mutations.
Read More
Thermo Fisher Scientific Signs Agreement with Janssen to Codevelop Companion Diagnostic for Cancer
Thermo Fisher Scientific will collaborate with Janssen scientists to validate multiple biomarkers, which will be used to identify variant-positive patients for enrollment into clinical trials focused on non-small cell lung cancer.
Read More